Gregory MacMichael, PhD

Cell and Gene Therapy Development and Manufacturing Expert

Career Highlights

  • President and Founder, CMC Bioservices

    • Highly experienced consultancy assisting innovator and biopharmaceutical companies with the successful development and licensure of cell and gene therapies, biologics and vaccines

  • Biopharmaceutical executive with 35 years of experience in the development and manufacture of biotherapeutic proteins, vaccines, and cell and gene therapies. Demonstrated ability to develop superior processes for manufacturing of bulk drug substances and final drug products

    • Axovant Gene Therapies

      • Led development and manufacturing for the production of lentiviral and AAV vectors

    • Rocket Pharmaceuticals

      • Led process development, manufacturing and quality assurance for internal and partnered cell and gene therapy assets. Aligned development and manufacturing on the appropriate strategies for developing and delivering the breakthrough technologies for ex vivo and in vivo gene therapies

    • Nantkwest

      • Led development and manufacturing of allogeneic NK92 platforms

    • Novartis

      • Developed and guided the strategy for delivering Novartis’s growing pipeline of novel cell and gene therapies. Aligning discovery, development and manufacturing on the appropriate technologies for developing the breakthrough CAR T technologies, stem cell and in vivo gene therapies

Education

  • PhD, Microbiology and Biochemistry: Mississippi State University

  • MS, Microbiology and Biochemistry: North Carolina State University

  • BS, Microbiology: Pennsylvania State University

Connect With Us

Cell One Partners

200 Central Park South

Suite 12Q

New York City, NY 10019

E: info@cellonepartners.com

© 2019 Cell One Partners